Galmed Pharmaceuticals (NASDAQ:GLMD) Announces Quarterly Earnings Results

Galmed Pharmaceuticals (NASDAQ:GLMD) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, FiscalAI reports.

Galmed Pharmaceuticals Trading Up 0.2%

NASDAQ GLMD traded up $0.00 during trading on Wednesday, hitting $0.57. 40,853 shares of the company traded hands, compared to its average volume of 1,711,449. The company has a market capitalization of $3.12 million, a P/E ratio of -0.46 and a beta of 0.75. The business has a fifty day simple moving average of $0.60 and a 200 day simple moving average of $0.66. Galmed Pharmaceuticals has a 12 month low of $0.41 and a 12 month high of $2.34.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Galmed Pharmaceuticals has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.